Trametinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Trametinib |
| DrugBank ID | DB08911 |
| Brand Names (EU) | Mekinist |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.54% |
Approved Indication (EMA)
Melanoma Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1). Adjuvant treatment of melanoma Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stag
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | metastatic melanoma | 99.54% | DL |
| 2 | choroideremia | 99.31% | DL |
| 3 | non-cutaneous melanoma | 99.30% | DL |
| 4 | epithelioid cell melanoma | 99.28% | DL |
| 5 | eyelid melanoma | 99.26% | DL |
| 6 | scrotum melanoma | 99.21% | DL |
| 7 | CDK4 linked melanoma | 99.14% | DL |
| 8 | acral lentiginous melanoma (disease) | 99.14% | DL |
| 9 | amelanotic skin melanoma | 99.14% | DL |
| 10 | balloon cell malignant melanoma | 99.14% | DL |
| 11 | nodular malignant melanoma | 99.14% | DL |
| 12 | lentigo maligna melanoma | 99.14% | DL |
| 13 | superficial spreading melanoma | 99.14% | DL |
| 14 | malignant melanoma of the mucosa | 99.14% | DL |
| 15 | choroidal dystrophy, central areolar | 98.97% | DL |
| 16 | intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency | 98.74% | DL |
| 17 | bilateral parasagittal parieto-occipital polymicrogyria | 92.41% | DL |
| 18 | amyotrophic lateral sclerosis | 92.28% | DL |
| 19 | anus leiomyosarcoma | 91.47% | DL |
| 20 | uterine corpus epithelioid leiomyosarcoma | 91.31% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.